Identification and Evaluation of IGF1R and Its Associated Proteins as Targets and Design of Novel Inhibitors for Cancer Therapy
Journal of Cellular Biochemistry · 2025
DOI: 10.1002/jcb.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular Biochemistry, 2025. Verfasst von Tabrez Faruqui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India. Hauptthemen laut MEDLINE: Receptor, IGF Type 1, Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 49 Literaturangaben. Gefördert von: This work was supported by a grant from the SERB-DST (No: CRG/2023/001873) to Mohd Jamal Dar..
Abstract (Originalsprache)
The insulin‐like growth factor 1 receptor (IGF1R) is a crucial receptor tyrosine kinase involved in cellular growth, survival, and metabolism. Abnormal overexpression and activation are common in various cancers and contribute to tumor development and resistance to treatment. The STRING database was used to analyze the protein–protein interaction network of IGF1R and was visualized using Cytoscape to identify the key associated proteins. We assessed IGF1R and its associated protein expression levels across pan‐cancer types and compared them to healthy controls using a TNMplot and cBioPortal. The objective of this study was to identify novel, low‐toxicity inhibitors targeting the IGF1R and its associated proteins (e.g., AKT1 and EGFR) with better pharmacokinetic profiles for effective cancer treatment, including brain cancer. We screened 693 million drug‐like compounds and selected the top 400 for toxicity analysis using ProTox‐II, which identified 83 nontoxic candidates. These were categorized as either blood–brain barrier (BBB) permeant or impermeant. Molecular docking studies with AutoDock Vina 4.1 were performed on 17 target proteins, including IGF1R, with the top three compounds. Subsequently, molecular dynamics simulations using Desmond were conducted on the two most promising candidates: two BBB permeants and two impermeants. Our study identified six nontoxic IGF1R inhibitors and 16 other target protein inhibitors. Docking and MD simulations confirmed the potential of these compounds in targeted therapies. Notably, both BBB‐permeant and ‐impermeant compounds in complex with the target proteins showed stability over 50 and 400 ns molecular simulation experiments, highlighting their potential in cancer therapy and suggesting the need for further in vitro and in vivo validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India.
- Cancer Pharmacology Division, Council of Scientific and Industrial Research-Indian Institute of Integrative Medicine, Jammu, Jammu and Kashmir, India.
- Academy of Scientific and Innovative Research(AcSIR), Ghaziabad, Uttar Pradesh, India.
- Department of Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, Uttar Pradesh, India.
ORCID-Profile: Mohd Jamal Dar, Yusuf Akhter
Förderung
- This work was supported by a grant from the SERB-DST (No: CRG/2023/001873) to Mohd Jamal Dar.
Zitieren
APA
Faruqui, T., Akhtar, A., Showket, F., Dar, M. J., & Akhter, Y. (2025). Identification and Evaluation of IGF1R and Its Associated Proteins as Targets and Design of Novel Inhibitors for Cancer Therapy. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.70008
Vancouver
Faruqui T, Akhtar A, Showket F, Dar MJ, Akhter Y. Identification and Evaluation of IGF1R and Its Associated Proteins as Targets and Design of Novel Inhibitors for Cancer Therapy. Journal of Cellular Biochemistry. 2025. doi:10.1002/jcb.70008
BibTeX
@article{Faruqui2025,
author = {Faruqui, Tabrez and Akhtar, Aubaidah and Showket, Farheen and Dar, Mohd Jamal and Akhter, Yusuf},
title = {Identification and Evaluation of IGF1R and Its Associated Proteins as Targets and Design of Novel Inhibitors for Cancer Therapy},
journal = {Journal of Cellular Biochemistry},
year = {2025},
doi = {10.1002/jcb.70008}
}
EUVIMED